| 姜玉梅,徐艳艳,郭小红,俞小卫,钱 骅,肖 雪.吉非替尼联合PC化疗方案对表皮生长因子受体突变阳性晚期肺腺癌患者免疫功能、凋亡因子和肿瘤标志物的影响[J].,2023,(15):2974-2979 |
| 吉非替尼联合PC化疗方案对表皮生长因子受体突变阳性晚期肺腺癌患者免疫功能、凋亡因子和肿瘤标志物的影响 |
| Effects of Gefitinib Combined with PC Chemotherapy Regimen on Immune Function, Apoptotic Factors and Tumor Markers in Patients with Epidermal Growth Factor Receptor Mutation-Positive Advanced Lung Adenocarcinoma |
| 投稿时间：2023-02-09 修订日期：2023-02-28 |
| DOI：10.13241/j.cnki.pmb.2023.15.034 |
| 中文关键词: 吉非替尼 PC化疗 表皮生长因子受体 肺腺癌 免疫功能 凋亡因子 肿瘤标志物 |
| 英文关键词: Gefitinib PC chemotherapy Epidermal growth factor receptor Lung adenocarcinoma Immune function Apoptosis factor Tumor markers |
| 基金项目:江苏省药学会-奥赛康临床药学基金项目（A201820） |
|
| 摘要点击次数: 390 |
| 全文下载次数: 258 |
| 中文摘要: |
| 摘要 目的：探讨吉非替尼联合铂类加环磷酰胺（PC）化疗方案对表皮生长因子受体（EGFR）突变阳性晚期肺腺癌患者免疫功能、凋亡因子和肿瘤标志物的影响。方法：选取南通大学附属肿瘤医院2018年3月~2020年3月期间收治的92例EGFR阳性晚期肺腺癌患者，根据随机数字表法分为对照组（PC化疗）和实验组（吉非替尼联合PC化疗），各为46例。观察两组疗效、肿瘤标志物、免疫功能、凋亡因子变化情况、肿瘤无进展生存时间（PFS）、总生存时间（OS）和不良反应发生率。结果：实验组的客观缓解率、疾病控制率均高于对照组（P<0.05）。两组治疗后血清癌胚抗原（CEA）、细胞角蛋白-19片段（CYFRA21-1）、鳞状细胞癌抗原（SCC-Ag）水平较治疗前均下降，且实验组较对照组低（P<0.05）。治疗后两组CD8+升高，但实验组较对照组低；而治疗后CD3+、CD4+、CD4+/CD8+均下降，但实验组较对照组高（P<0.05）。两组治疗后血清Livin水平较治疗前下降，且实验组低于对照组（P<0.05），两组治疗后血清PDCD5、P53、Bax水平较治疗前均升高，且实验组均高于对照组（P<0.05）。两组不良反应发生率组间对比无明显差异（P>0.05）。实验组的PFS、OS高于对照组（P<0.05）。结论：吉非替尼联合PC化疗方案治疗EGFR突变阳性晚期肺腺癌患者，可调节血清凋亡因子和肿瘤标志物水平，有效改善患者的免疫功能和预后。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of gefitinib combined with platinum plus cyclophosphamide (PC) chemotherapy on immune function, apoptotic factors and tumor markers in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced lung adenocarcinoma. Methods: 92 patients with EGFR-positive advanced lung adenocarcinoma who were admitted to our hospital from March 2018 to March 2020 were selected, and they were divided into the control group (PC chemotherapy) and the experimental group (gefitinib combined with PC chemotherapy) according to random number table method, with 46 cases each. Efficacy, tumor markers, immune function, apoptotic factors change of situation, progression-free survival time (PFS), overall survival time (OS) and the incidence of adverse reactions were observed in the two groups. Results: The objective remission rate and disease control rate in the experimental group were higher than those in the control group (P<0.05). The levels of serum carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1) and squamous cell carcinoma antigen (SCC-Ag) in the two groups after treatment decreased, and the experimental group was lower than the control group (P<0.05). After treatment, CD8+ increased in the two groups, but the experimental group was lower than the control group. After treatment, CD3+, CD4+, CD4+/CD8+ all decreased, but the experimental group was higher than the control group (P<0.05). After treatment, the level of serum Livin in the two groups decreased compared with that before treatment, and the experimental group was lower than the control group (P<0.05), the levels of serum PDCD5, P53 and Bax in the two groups after treatment were higher compared with those before treatment, and the experimental group was higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions in the two groups (P>0.05). PFS and OS in the experimental group were higher than those in the control group (P<0.05). Conclusion: Gefitinib combined with PC chemotherapy can regulate the levels of serum apoptosis factors and tumor markers, and effectively improve the immune function and prognosis of patients with EGFR mutation-positive advanced lung adenocarcinoma. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
